Opparounds

Thursday, August 27, 2026

Opparounds

01
πŸ”¬Psychiatric Research Article

Integrated mental health treatment and employment services for refugees with PTSD: randomised controlled trial

Maja Bruhn, Henriette Laugesen Attardo, Hinuga Sandahl, Lene Falgaard Eplov, Carsten HjorthΓΈj, Jessica Carlsson Β· BJPsych Open Β· August 2026

This Danish trial randomized 195 refugees with chronic PTSD and unemployment at a specialized transcultural psychiatry clinic in Copenhagen to usual care (psychologist plus physician over 8-12 months) or that same usual care plus structured, intersectoral collaboration with employment services.

On the primary outcome β€” WHODAS functional disability β€” the integrated arm showed no advantage over usual care alone (mean difference 0.30, 95% CI -2.40 to 3.00, P=0.825), and secondary symptom measures were similarly flat, with only modest gains across both arms.

Adding the employment-services layer did significantly cut early dropout (P=0.042) and raise treatment satisfaction (P=0.035), even without moving functioning.

 
πŸ’‘ Why it matters

In refugees with long-standing PTSD and prolonged unemployment, bolting vocational coordination onto usual trauma care improves engagement but not function β€” it may need to arrive earlier, before disability entrenches, to change outcomes rather than just retention.

Read the paper β†’  doi:10.1192/bjo.2026.12070

02
πŸ“–Psychotherapy Research Article

Integrated therapist and online cognitive behavioural therapy in addition to usual care versus usual care for depression in primary care in England (INTERACT): a two-group, parallel, multicentre, randomised controlled trial

Debbie Tallon and colleagues (University of Bristol, with Glasgow, York, UCL, and University College Dublin) Β· The Lancet Primary Care Β· August 2026

451 adults with depression across 67 GP practices in England were randomized to usual GP care alone or usual care plus "integrated CBT" β€” 9 to 12 sessions of therapist-led CBT delivered by real-time instant messaging, paired with an interactive online workbook both patient and therapist could access between sessions.

At 6 months, the integrated-CBT group's depression score averaged 4.4 points lower than usual care, a difference the authors judged clinically important, and the gain held out to 12 months.

The design targets a known gap: pure self-guided online CBT is accessible but suffers poor adherence and modest, short-lived effects without a therapist attached, while high-intensity face-to-face CBT is often unavailable β€” INTERACT keeps a real therapist in the loop while moving delivery to asynchronous messaging.

 
πŸ’‘ Why it matters

For patients facing real barriers to in-person therapy β€” scheduling, distance, stigma β€” text-based therapist-delivered CBT looks like a legitimate middle path between self-help apps and traditional face-to-face treatment, not just a stopgap.

Read the paper β†’  doi:10.1016/j.lanprc.2026.100164

03
πŸ’ŠPsychiatric Fact

Amiloride treats lithium's nephrogenic diabetes insipidus by closing the door lithium walks through

About 20% of patients on chronic lithium develop nephrogenic diabetes insipidus (NDI), driven by lithium accumulating inside collecting-duct principal cells and downregulating aquaporin-2 water channels. The entry route is the lever: lithium reaches those cells through the same apical epithelial sodium channel (ENaC) that normally reabsorbs sodium. Amiloride blocks ENaC directly, which cuts off lithium's transcellular entry, lowers intracellular lithium, and restores AQP2 expression and urine-concentrating ability β€” without stopping the lithium itself. Typical dosing is 5-10 mg twice daily, often combined with a thiazide (e.g., hydrochlorothiazide 25-50 mg/day), which paradoxically reduces urine volume in NDI by increasing proximal water and sodium reabsorption. That pairing is a trap as much as a treatment: thiazides are also the class best known for raising serum lithium by increasing its proximal reabsorption. Anyone started on this combination needs a lithium level within about a week and closer monitoring after, since the fix for the NDI and the interaction that can push the patient toward toxicity come from the same two drugs.

04
πŸ›‹οΈPsychotherapy Teaching Pearl

Optimal frustration is not empathic failure β€” it's how structure gets built

Kohut's self psychology holds that psychic structure β€” the capacity to regulate one's own self-esteem and soothe oneself β€” isn't installed by an unbroken supply of perfect attunement. It's built through repeated, small, tolerable failures of empathy from a needed selfobject, followed by the selfobject's acknowledgment and the patient's own work to restore equilibrium. Too much perfect attunement leaves nothing for the patient to metabolize; each survivable micro-failure, correctly timed and correctly small, is an occasion for transmuting internalization β€” an external function (the therapist regulating the patient's affect) gradually becoming an internal one (the patient regulating their own). The technical implication cuts against instinct: chasing flawless empathic accuracy to protect a fragile patient can starve the very structure-building the treatment depends on.

 
πŸ—’οΈ Vignette

A patient with chronic inner emptiness idealizes his therapist β€” arriving early, quoting her from memory, visibly soothed just by her presence. When she is fifteen minutes late after months of reliability, he turns coldly polite, then admits feeling "stupid for caring." Rather than rushing to reassure him it won't happen again, she names the disappointment plainly β€” "something dropped out from under you when I wasn't there" β€” and lets him sit with it before either of them moves toward repair. Unprompted, he works out that he survived her ordinariness. That small, tolerated gap, not her usual reliability, is what does the structural work.

05
πŸ“°In the News
β€’ The FDA approved centanafadine (Simtriyo) on July 24, 2026 β€” the first norepinephrine-dopamine-serotonin reuptake inhibitor for ADHD in adults and children 6+, a non-stimulant, non-Schedule-II option worth knowing amid ongoing stimulant supply constraints.  source β†’
β€’ In a January 2026 safety communication, the FDA asked manufacturers to drop the suicidal-ideation/behavior warning from GLP-1 agonist labels (semaglutide, liraglutide, tirzepatide) after a meta-analysis of 91 trials and 107,910 patients found no signal β€” useful reassurance given how many psychiatric patients are now on these drugs.  source β†’